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Atrial Fibrillation (AF) is a common arrhythmia with an incidence that is as high as 10% in the elderly population. Given the
large proportion of strokes caused by AF as well as the associated morbidity and mortality, reducing stroke burden is the most
important part of AF management. Whilewarfarin signiﬁcantlyreduces the risk of AF-related stroke, perceived bleeding risks and
compliance limit its widespread use in the high-risk AF population. The left atrial appendage is believed to be the “culprit” for
thrombogenesis in nonvalvular AF and is a new therapeutic target for stroke prevention. The purpose of this review is to explore
theevolving ﬁeld ofpercutaneous LAA occlusion.After brieﬂy highlightingthe riskof strokewith AF, problems with warfarin,and
therole ofthe LAAin clotformation,this article discussesthe feasibilityandeﬃcacy of various devices which have been developed
for percutaneous LAA occlusion.
1.Introduction
Atrial ﬁbrillation (AF) is the most common sustained ar-
rhythmia encounteredinclinicalpractice.Ithas an estimated
prevalence of 1% in the adult population translating into
greater than two million cases in the United States [1]. The
projected number ofindividualswith AFinthe UnitedStates
of America is expected to be approximately 10 million by
2050 [2]. With better methods of diagnosing AF, especially
paroxysmal AF, as well as increasing physician awareness,
the actual burden may be higher than expected. AF is
fraught with the serious complication of thromboembolism.
Althoughanticoagulationiseﬀective,patientsandphysicians
both seek alternative means to avert the risk of stroke
from thromboembolism due the need for monitoring and
bleeding complications as well as the potential for drug
interactions. Left atrial appen d a g e( L A A )c l o s u r ed e v i c e s
have become an attractive option for this purpose. In
this review, we will summarize the available literature and
evidenceforuseofpercutaneousleftatrialappendageclosure
as an alternative to chronic anticoagulation.
2.StrokeRiskinAtrialFibrillation
AFincreasestheriskofstrokeby4to5foldsinnonrheumatic
patients [3] and 17 folds in the setting of rheumatic mitral
stenosis [4]. It is responsible for 10% of all ischemic strokes
and half of all cardioembolic strokes [5]. The impact of AF
as a risk factor for stroke increases with age. While the an-
nual incidence of stroke due to atrial ﬁbrillation is 1.5% in
patients aged 50–59 years, almost a quarter of the strokes in
patients aged 80 to 89 years are secondary to AF [3]. Per-
ceived adverse eﬀects related to anticoagulation also increase
with age, which may result in a paradoxical underuse in a
population at highest risk for stroke [6].
Paroxysmal AF (PAF), which accounts for 25% of AF,
has the same risk of stroke as permanent/persistent AF [7].
In a recent study, up to 23% patients with stroke/TIA of
unknown etiology (cryptogenic stroke) were found to have
PAF on subsequent monitoring [8]. Given that cryptogenic
stroke accounts for 36% of all strokes [9], the stroke burden
attributed to PAF has been hitherto signiﬁcantly underesti-
mated. With better methods of diagnosing PAF in patients2 Cardiology Research and Practice
with cryptogenic stroke, such as transtelephonic EKG moni-
toring [10] and mobile cardiac outpatient telemetry [8], the
number of patients potentially requiring anticoagulation is
expected to increase in the future.
Apart from a sheer increase in numbers, AF-related
strokes also tend to be more severe when compared to other
causes of thromboembolism, likely due to the larger size
of thrombi [11, 12]. Consequently, there is a signiﬁcant im-
pact on the quality of life as well as longevity with an esti-
mated 28-day mortality of 20% post-AF-related stroke [13].
Thus, reducing the stroke burden is a sine qua non of AF
management.
3.UnderuseofAnticoagulationinAF
Warfarin dramatically decreases the risk of stroke in patients
with valvular as well as nonvalvular AF. In a meta-analysis
of randomized controlled trials, warfarin resulted in a
64% relative risk reduction for stroke when compared to
placebo[14].Another meta-analysis revealed thatwarfarin is
almost three times more eﬀective than antiplatelet agents in
preventing strokes (relative risk reduction 64% for warfarin
versus 20% for antiplatelet agents) [15].
However, several studies have reported underuse of
warfarin ineligiblepatientswithAF.Inalargecross-sectional
study, 45% patients with moderate to high-risk AF did not
receive warfarin [16]. Similarly, a recent cohort study of
Medicare beneﬁciaries with atrial ﬁbrillation revealed that
only two thirds of ideal anticoagulation candidates were
prescribed warfarin, with signiﬁcant diﬀerencesin use, mon-
itoring, and eﬀectiveness of warfarin among diﬀerent ethnic
groups [17]. Given the high incidence of atrial ﬁbrillation
and associated risk factors for stroke, a small percentage
of underuse could translate into a huge hurdle to stroke
prevention in the population.
Table 1 outlines important reasons for warfarin under-
utilization. Fear of major bleeding, especially hemorrhagic
strokes and gastrointestinal bleeding, is a major reason for
this underuse [18, 19]. This fear is not without reason; a
meta-analysis revealed that the risk of intracranial hem-
orrhage is doubled with warfarin when compared with
aspirin [15]. Anticoagulants ranked ﬁrst in 2003 and 2004
in the number of deaths from drugs causing “adverse eﬀects
in therapeutic use” [20]. The perceived risk is greater in
elderly patients with AF [21], and “fall risk” is estimated
in rather ambiguous ways in this population. Inconvenience
of INR monitoring for rural populations, drug, and dietary
interactions as well as compliance are other limiting factors
[22]. For unclear reasons, warfarin is also underused in
females compared to males [23].
Novel anticoagulants, such as the thrombin inhibitors
(dabigatran) and the factor Xa inhibitors (rivaroxaban) have
a wider therapeutic window. There is minimal dietary and
drug interference with these agents and INR monitoring is
notrequired.While thesemay decrease many oftheconcerns
associated with warfarin, they do not address issues related
to bleeding and compliance [24]. A case in point is that
of dabigatran, which is superior to warfarin in preventing
Table 1: Causes of warfarin underutilization.
(1) Risk of bleeding (perceived or real)
(a) Intracranial hemorrhage
(b) Gastrointestinal bleeding
(c) Other major bleeds (retroperitoneal, hematuria, etc.)
(2) Perceived Fall Risk (and associated bleeding risk)
(3) Diﬃculty with INR monitoring
(a) Geographical barriers
(b) Lack of insurance/primary care physician
(4) Non-compliance
(5) Patient preference
(6) Physician unawareness (such as need in paroxysmal AF∗)
(7) Pharmacokinetic interference
(a) Drug interaction
(b) Dietary interference
(8) Ethnic and gender disparities
∗AF: atrial ﬁbrillation.
s t r o k e sb u th a sas i m i l a rr i s ko fm a j o rb l e e d i n ga tt h e
currently approved dose [25]. Similarly, there was no diﬀer-
ence in major bleeding event rates between rivuroxaban and
warfarin groups in the recent ROCKET-AF trial [26]. Also,
cost-eﬀectiveness and eﬃcacy of these novel agents in real
world setting remain to be seen.
4.LeftAtrialAppendage:TheCulprit?
The left atrial appendage is an embryological remnant
that functions during conditions of volume overload as a
reservoir and mediator of adaptive responses to decrease
circulating blood volume [27]. Compared to the right atrial
appendage, the LAA is anatomically prone to stasis by virtue
of having a long, tubular structure as well as a narrow
junction with the atrium [28]. Multiple studies have found a
predilectionforthrombustoformwithintheLAAinpatients
with mitral valve disease (irrespective of underlying rhythm)
and nonvalvular AF.
The hematological and endocardial substrate for throm-
bogenesisintheLAAisyettobeelucidated,butthestructural
basis has been deﬁned. All known variables associated with
thrombus formation, including LAA size and ﬂow pattern,
are altered due to AF-associated LAA dysfunction [27]. Post-
mortem LAA cast analysis from patients with AF revealed
that its size was much larger in patients with AF [29].
A speciﬁc type of LAA ﬂow pattern in patients with AF
(Type III indicating no identiﬁable ﬂow waves with AF) was
associated with a higher incidence of LAA thrombus [30].
These represent the macroscopic basis of LAA thrombus
formation in the setting of AF.
IncontrasttopatientswithvalvularAF,itishypothesized
that the LAA may be the major source for emboli in nonva-
lvular AF. This is based on an analysis of 23 studies utilizing
echocardiographic, operative, and postmortem evaluations
of the left atrium and LAA in patients with AF (Table 2). The
percentage of thrombi found in the LAA was signiﬁcantly
higher in patients with nonvalvular AF than in valvularCardiology Research and Practice 3
Table 2: Left atrial appendage as a source of thrombi in nonatrial
ﬁbrillation.
(i) Hypothesis is based on a landmark study by Blackshearand
Odell [31]
(ii) Findings from studies in settings of operation, autopsy, or
transesophageal echocardiography were combined
(iii) 23 studies including close to 5,000 subjects with rheumatic
or nonrheumatic AF∗ were reviewed
(iv) Thrombi presented in the appendage but extending into the
a t r i u mw a sc l a s s i ﬁ e da saL A A ∗∗ thrombus
(v) While 57% of atrial thrombi in rheumatic AF occurred in the
appendage, 91% of left atrial thrombi were located in the atrial
appendage in nonrheumatic AF (P<. 0001)
(vi) Many have pointed out that merely ﬁnding a thrombus in the
LAA does not prove that it is the source of cardio-emboli in
AF-related ischemic stroke [32]
(vii) This study set the stage to investigate the beneﬁt of LAA
occlusion in reducing nonrheumatic AF-related stroke burden
∗AF: atrial ﬁbrillation; ∗∗LAA: left atrial appendage.
AF (91% versus 57%; P<. 001) [31]. This data, however,
does not conﬁrm that the LAA is the “source” of emboli
in AF-related ischemic stroke, and many have questioned
this theory [32]. Nevertheless, many surgical as well as non-
invasive methods to occlude the LAA have been assessed to
reduce stroke burden and conﬁrm this hypothesis.
5.MethodsofLAAOcclusion
5.1. Surgical. Several studies have assessed the feasibility,
safety, and eﬃcacy of surgical LAA occlusion [33, 34].
Given its invasive nature, surgical LAA occlusion is only
performed in patients requiring other cardiac surgery such
as mitral valve surgery and maze procedures. The addition
of this simple, quick procedure to the aforementioned
surgeries can reduce stroke burden in many patients with
established AF or at high risk for AF. However, its eﬃcacy
for occluding the LAA and preventing thromboembolic
events has been questioned, with a study demonstrating
that surgical LAA occlusion is frequently incomplete [35].
Continuous advancements in open surgical LAA occlusion
technique are being made with better methods for intra-
operative conﬁrmation of success (TEE), and outcomes are
expected to improve in the future.
5.2. Nonsurgical. There are several percutaneous devices,
which have been used for LAA occlusion. Of these, only the
WATCHMAN device is FDA approved. Table 3 summarizes
studies, which have analyzed the feasibility and eﬃcacy of
diﬀerent devices.
6.TheAmplatzerSeptalOccluder(AGAMedical
Corp.,GoldenValley, Minn)
The Amplatzer septal occluder, which was originally used
for patent foramen ovale or atrial septal defect closure,
was tested for LAA closure in a preliminary analysis of 16
patients across four centers [36] .T h e r ew a sas i n g l ee v e n to f
asymptomatic deviceembolization duetoinappropriatesize;
no other complications or thromboembolic episodes were
reported in a short followup period of four months. How-
ever,nofurthertrialswereconductedwiththissystem, which
paved the way for the LAA-speciﬁc devices. The Amplatzer
Cardiac Plug is another device by the same manufacturer
which is currently being compared with warfarin in the
Amplatzer Cardiac Plug trial.
7.The PLAATOSystem(eV3,Plymouth,Minn)
The PLAATO implant consists of a self-expanding nitinol
cage coated with a special expanded polytetraﬂuoroethylene
(ePTFE) membrane to occlude blood ﬂow into the oriﬁce
while allowing tissue incorporation. The ePTFE membrane
ensures benign healing [42], resulting in endothelialization
of the implant in 2 to 3 months. A custom 14Fr transseptal
sheath is used to deliver the implant into the LAA, and small
anchors along the struts of the implant hold it in position.
After initial animal studies conﬁrmed safe LAA occlusion
with this system [43], a feasibility study was conducted
in Europe in 15 patients with chronic, nonrheumatic AF
and contraindications to warfarin therapy [37]. All patients
were at high risk for thromboembolism based on CHADS2
criteria [44] or spontaneous echo contrast in the LAA on
TEE. The device was successfully implanted in all patients
with an average implant time of 90 minutes. Periprocedural
hemopericardium delayed successful implantation in one
patient by a month, and the device needed to be exchanged
duetoinappropriatesizein4patients.Aonemonthfollowup
showed stable implant position, and there were no reported
late complications or embolic events. An addendum to
this study reported successful implantation in 16 additional
patients (with another case of hemopericardium).
Subsequently, the larger PLAATO multicenter study
reported results from multiple sites in North America and
Europe with a followup period of up to 17 months [38].
Patients with nonrheumatic AF of at least three months
durationwith contraindications towarfarin andhigh riskfor
thromboembolic events were included. The latter was based
on CHADS2 criteria, presence of coronary artery disease,
or echographic criteria (moderate to dense spontaneous
echocardiographic contrast or blood ﬂow velocity <20cm/s
within the LAA), thus expanding inclusion criteria from the
previous feasibility study. Percutaneous LAA occlusion was
successful in 108 of 111 patients, with an average procedure
time of 68 minutes. There were two reported major adverse
events in a single patient within the ﬁrst month. A total of
5 patients (4.5%) experienced hemopericardium during the
entire followup; fourofthese ﬁve had no long-termsequelae.
Based on a mean CHADS2 score of 2.5, the estimated stroke
riskinthepopulationwas6.5%.Thiswasreducedtoalmosta
third (2.2%/year) withthe PLAATOsystemfor strokesalone;
TIA was not included.
The largest feasibility study for the PLAATO system was
conducted in North-America and utilized a prospective,
nonrandomized study design enrolling 64 patients across4 Cardiology Research and Practice
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10 centers [39]. The inclusion criteria for this study were
broader than the previous, smaller feasibility studies. Due
to the similar risk for thromboembolic events, patients
with either permanent or paroxysmal AF were selected for
inclusion. Risk for developing thromboembolic events was
deﬁned by a CHADS2 score ≥2 or the presence of any of the
multiple high-risk echocardiographic ﬁndings. More than
98% of the patients met the primary end point of no major
adverseevents(i.e.,stroke,cardiac, orneurologicaldeath,MI
orrequirementofsurgeryrelatedtothePLAATOprocedure).
In the ﬁve-year followup, there was only one adverse event
(cardiac tamponade) attributed to the procedure, indicating
an improved safety proﬁle with time and experience (the
learningcurveeﬀect).There were no otherprocedure-related
adverse events, device failures, or malfunctions throughout
the study period. The estimated yearly combined rate of
stroke/TIA was 6.6%, calculated from the mean CHADS2
score of 2.6 in the study population. This was reduced to
a rate of a 3.8%/year with the PLAATO system. Despite
the encouraging results, there were no subsequent studies
comparing the device to warfarin therapy.
8.WATCHMANDevice (AtritechInc.,
Plymouth,Minn)
Similar to the PLAATO implant, the WATCHMAN LAA
closuredeviceconsistsofaself-expanding nitinolframe [41].
It also has ﬁxation barbs; however, the permeable polyester
fabric only covers the surface exposed to the left atrium. It
is available in ﬁve diﬀerent sizes ranging from a diameter of
21 to 33mm. The implant is preloaded within a catheter and
requires an access sheath for delivery into the LAA.
A preliminary feasibility study tested this device in
75 patients across multiple centers in Europe and North
America. Subjects with chronic or paroxysmal nonvalvular
AF eligible for warfarin therapy and a CHADS2 score ≥1
were included [40], thus having broader inclusion criteria
than feasibility studies for PLAATO. After implantation,
patients were discharged on warfarin which was discon-
tinued at 45 days if LAA remained successfully sealed by
echocardiographic criteria. The initial 16 patients received
the ﬁrst generation device. The device was subsequently
redesigned and implantation of a second-generation device
was attempted in 59 patients. Adverse eﬀects were much
lesser with second- than ﬁrst-generation device, including
core wire failure (0/59 versus 2/16), device embolization
(0/59 versus 2/16), and internal bleeding (0/59 versus 1/16).
Though minor pericardial eﬀusions were more common
with the second-generation device (3/59 versus 0/16 with
ﬁrst generation), there was one case of pericardial eﬀusion
requiring treatment in each group. Based on the CHADS2
score, theexpected annual stroke risk of 1.9%was reduced to
0% with this device over a followup period of two years.
The PROTECT AF(WATCHMANLeft Atrial Appendage
System for Embolic Protection in Patients with Atrial
Fibrillation) is the ﬁrst study that directly compared a
LAA occlusion device head-to-head with warfarin therapy
[45]. It was primarily designed to assess noninferiority of
the WATCHMAN device against warfarin. This prospective
randomizedcontroltrialusedinclusioncriteriasimilar tothe
initial feasibility study, choosing patients with paroxysmal,
persistent or permanent nonvalvular atrial ﬁbrillation, and
a CHADS2 score of ≥1. A computer-generated sequence
randomized selected patients (n = 707) to the device
(n = 463) and warfarin therapy (n = 244) in a 2:1 ratio.
Those randomized to intervention subsequently discontin-
ued warfarin after transesophageal echocardiographic (TEE)
demonstration of complete LAA closure or a residual jet
<5mm in width. Following this, dual antiplatelet therapy
(aspirin and clopidogrel)was prescribed until the end of a 6-
month followup period. This was in contrast to the PLAATO
recipients, who only received dual antiplatelet therapy for
four to six weeks without any warfarin therapy. The device
was successfully implanted in 88% of those assigned to the
intervention group, ofwhich 92% couldstop taking warfarin
at 6 months. The primary eﬃcacy event rate for occurrence
of stroke (ischemic or hemorrhagic), cardiovascular or
unexplained death, or systemic embolism was 3/100 patient-
years in the intervention group and 4.9/100 patient-years
in the control group (rate ratio [RR] 0.62, 95% CI 0.35–
1.25) with a greater than 99% probability of noninferiority.
Though the primary safety event rate for occurrence ofhem-
orrhage or procedure related complications was greater in
the intervention group of the “intention to treat” population
(7.5 versus 4.4 per 100 patient-years; RR 1.69 (95% CI 1.01–
3.19)), the rate was higher in the control group amongst
those successfully treated with device or warfarin (1.5 versus
4.4 per 100 patient-years; RR 0.35 (95% CI 0.15–0.80)).
There were several concerns about the trial design,
such as using a noninferiority hypothesis to compare two
diﬀerent modalities of treatment, that is, a drug and a
device. The risk of hemorrhagic stroke in the warfarin
group (1.6 per 100 patient-years) was much higher than
that reported in previous trials (0.5 per 100 patient-years
in a meta-analysis of 6 randomized clinical trials [46])
and this may have inﬂuenced the noninferiority results for
primary eﬃcacy. Also, the rate of serious pericardial eﬀusion
requiring drainage was fairly high in the device group (4.8%
versus 0%). The FDA has recommended longer followup
studies with this device, and another trial is being planned
by investigators.
9.FuturePerspective
PercutaneousLAAocclusiondevicesmay represent the“holy
grail” in reducing nonvalvular AF-related stroke burden.
Researchers have been constantly looking for easier methods
for this, and a single procedure with short-term anticoag-
u l a t i o ni sm o r ef e a s i b l et h a nl ife-long anticoagulation and
associated bleeding risks. Oral anticoagulants may become
“alternative” agents in nonvalvular AF subjects who are not
suitable for device implantation.
However, there are many questions that remain unan-
swered. Though only the WATCHMAN device is under
consideration for FDA approval, results from feasibility
studies of PLAATO are encouraging. A trial with the6 Cardiology Research and Practice
Amplatzer Cardiac Plug device is also underway. Long-term
studies with these devices and head-to-head comparisons
may be necessary before deciding the “best” device. Dif-
ferent trials have used varied regimens for periprocedural
antiplatelet/anticoagulant therapyand contrasting thesepro-
tocols is imperative. If postprocedural warfarin therapy is
needed, populations at high-risk or ineligible for warfarin
therapy may also be unsuitable for device implantation. This
will leave a huge proportion of the AF population at high-
risk for stroke without any therapeutic modality. Despite the
beneﬁt of LAA occlusion, procedure-related adverse events
such as pericardial eﬀusion and device embolization remain
concerning. Once this procedure gains popularity, longer
followup studies in real-world settings will help assess the
actual risk of adverse events. The role of this device in the
face of newer, safer, and more eﬃcaciousoral anticoagulants,
such as dabigatran and rivoroxaban, also remains to be seen.
Arecentindirect comparisonofdata fromthePROTECT-AF
andRE-LYtrialrevealedthattheWatchman devicewouldfail
to meet noninferiority when compared to dabigatran [47].
Prospective, head-to-head trials are required to address this
question.
10.Conclusion
While warfarin has signiﬁcantly reduced stroke risk in
patients with AF, it is still underused secondary to perceived
risk for hemorrhagic complications and drug interactions.
The LAA is considered to play a major role in thromboge-
nesis in patients with nonvalvular AF and is a new target
for stroke prevention. The FDA has withheld the approval
of WATCHMAN device, and better designed trials with a
longer followup are necessary to evaluate this method in
comparison to warfarin and novel oral anticoagulants.
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